Dr Moore on Investigating Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer

Kathleen N. Moore, MD, MS, associate director of Clinical Research, the Stephenson Cancer Center, director of the Oklahoma TSET Phase I Program, professor, the Section of Gynecologic Oncology, The University of Oklahoma College of Medicine, discusses the investigation of ubamatamab (REGN4018) alone or in combination with cemiplimab-rwlc (Libtayo) in patients with recurrent ovarian cancer.

The bispecific antibody ubamatamab is designed to bridge MUC16 on cancer cells with CD3-expressing T cells to facilitate T-cell activation and cytotoxicity, Moore begins. Data from a phase 1 trial (NCT03564340) presented at the 2022 ESMO Congress showed that among 42 patients with heavily pretreated ovarian cancer who received at least 1 dose of ubamatamab at 20 mg or higher, the overall response rate was 14.3% and the disease control rate was 57.1%.

Traditional checkpoint inhibitors have produced modest to no efficacy for patients with ovarian cancer, and bispecific antibodies could represent a different way to harness the immune system in the treatment of these patients, Moore says.

At the 2023 ASCO Annual Meeting, Moore and colleagues presented a poster on an ongoing phase 2 trial (NCT03564340) that is evaluating 2 different doses of ubamatamab monotherapy and the combination of ubamatamab and cemiplimab in patients with advanced platinum-resistant ovarian cancer. Patients are being randomly assigned 1:1:1 to receive intravenous (IV) ubamatamab at 250 mg once every 3 weeks, IV ubamatamab at 800 mg once every 3 weeks, or the combination of IV ubamatamab at 250 mg and cemiplimab at 350 mg once every 3 weeks.

The goal of the study is to better understand the optimal treatment dose and determine if combination is superior to monotherapy in order to help further define the clinical pathway for ubamatamab, she concludes.